Akelos

company

About

Akelos is a biopharmaceutical company that focuses on the translation of innovative science into treatment.

  • 11 - 50

Details

Last Funding Type
Grant
Last Funding Money Raised
$1.75M
Industries
Biopharma,Biotechnology,Health Care,Pharmaceutical
Founded date
Jan 1, 2018
Number Of Employee
11 - 50
Operating Status
Active

Akelos is a biopharmaceutical company that focuses on the translation of innovative science into treatment. The company currently is developing novel non-narcotic drugs for the treatment of neuropathic pain. It was founded to address the Opioid epidemic through opioid alternatives, with two drug candidates in pre-clinical development. Akelos has proudly entered into a research collaboration to develop and commercialize a novel, non-opioid anti-hyperalgesic drug to treat chronic and neuropathic pain.

The goal of Akelos is to address some of today’s most pressing areas of unmet needs. The company was founded in 2018 and is based in New York, NY, United States.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$1.75M
Akelos has raised a total of $1.75M in funding over 2 rounds. Their latest funding was raised on Jan 22, 2020 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jan 22, 2020 Grant $1.75M 1 National Institutes of Health Detail

Investors

Number of Lead Investors
Number of Investors
1
1
Akelos is funded by 1 investors. National Institutes of Health are the most recent investors.
Investor Name Lead Investor Funding Round
National Institutes of Health Yes Grant